Specify a stock or a cryptocurrency in the search bar to get a summary
RetinalGenix Technologies Inc
RTGNRetinalGeniX Technologies Inc., an ophthalmic research and development company, focuses on developing solutions to screen, monitor, diagnose, and treat ophthalmic, optical, and sight-threatening disorders. Its products include the Retinal Imaging Screening Device, a portable retinal imaging system providing a wide field of view without requiring pupil dilation; and RetinalCam, an in-home/remote location patient-activated monitoring and imaging device offering real-time communication and alerting system for physicians. It also develops RTG-2023 for the treatment of dry age-related macular degeneration; and RTG-2024 for the treatment of Alzheimer's syndrome dementia. The company was incorporated in 2017 and is based in Petaluma, California. RetinalGenix Technologies Inc. is a subsidiary of Sanovas Ophthalmology, LLC. Address: 1450 North Mcdowell Boulevard, Petaluma, CA, United States, 94954
Analytics
WallStreet Target Price
–P/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures RTGN
Dividend Analytics RTGN
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History RTGN
Stock Valuation RTGN
Financials RTGN
Results | 2019 | Dynamics |